Outsourcing gap widens: Europe pulls away from US in new drug manufacturing - Pharmaceutical Technology

The industry looks set to continue a preference for European outsourcing facilities as national tax systems exert influence. The industry looks set to continue a preference for European outsourcing facilities as national tax systems exert influence. In 2025, 50% of new drugs had dose manufacturing contracts with European-based facilities, almost doubling their share since 2023. Credit: GagoDesign/Shutterstock.com. In 2025, the dose outsourcing gap between the proportion of newly approved biosimilar and innovator products outsourced to European and US facilities was the widest yet, with Europe taking a substantial lead. The first half of 2026 is continuing that trend. Contract manufacturing…

Source: Pharmaceutical Technology